

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

HENSEN, ET AL.

Serial Number: To be assigned

Group Art Unit: To be assigned

Filed: February 10, 2005

Examiner: To be assigned

For: Streptococcus uberis protein, nucleic acid sequence encoding the same and its use in a mastitis vaccine

Corresponding to: PCT/EP2003/008704 filed August 6, 2003

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97(b)

Honorable Assistant Commissioner of Patents
Alexandria, VA 22313
February 10, 2005

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-SB-08A and PTO-SB-08B. These references were cited in the parent case a Search Report for the corresponding European application. Copies of the S cited references are enclosed.

No fee or certification is required in connection with this Information Disclosure Statement, since it is being submitted prior to the last of (1) issuance of a first official action on the merits and (2) expiration of the three month period following filing of the above-captioned


Attorney Docket No.: I-2002.013 US
Customer No.: 31846
Express Mail: EV 561841541 US

application.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. It is respectfully requested that the information be considered during the prosecution of this application and that the cited documents be listed on the front page of any patent issuing from this application.

The Patent Office is authorized to charge our Deposit Account No. 02-2334 for any fee which it deems to be required to effect consideration of this statement.

Respectfully submitted,



William P. Ramey, III

Attorney for Applicants

Registration No. 44,295

Akzo Pharma Patent Department
P.O. Box 318
29160 Intervet Lane
Millsboro, DE 19966
Tel: (302) 934-4395
Fax: (302) 934-4305

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Express Mail: EV 561841541 US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number To Be Assigned

Filing Date February 10, 2005

First Named Inventor HENSEN, Selma M.

Art Unit To Be Assigned

Examiner Name To Be Assigned

Attorney Docket Number I-2002.013 US

Sheet

1

of

1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		DATABASE EPOFETCH [Online!] (07/01/2002) Database accession no. ABN68115, XP002228319	
		DATABASE EPOFETCH [Online!] (07/02/2002) Database accession no. ABP27484, XP002228320	
		DATABASE SWISS-PROT [Online!] (06/15/2002) Database accession no. Q8P120, XP002228321	
		DATABASE EMBL [Online!] (03/23/2002) Database accession no. AE010036, XP002228322	
		TYLER, J.W. ET AL.: "Immunization and immunotherapy for mastitis" Veterinary Clinics of North America (11/01/1993) V9, N3 p 537-549, XP002095921	
		FONTAINE, M.C. ET AL.: "Immunisation of dairy cattle with recombinant Streptococcus uberis GapC..." Vaccine Butterworth Scientific. (05/22/2002) V20 N17-18, p2278-228	
		LEIGH, J.A. "Streptococcus uberis: A Permanent Barrier to the Control of Bovine Mastitis?" Veterinary Journal, (May 1999) V157, N3, p 225-238, XP009020371	
		VERMEULEN, A.N. "Progress in recombinant vaccine development against coccidiosis A review..." International J. of Parasitology (July 1998) V28, N7, P1121-1130, XP001024960	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Express Mail: EV 561841541 US